PLAU and melanoma: A polyclonal antibody recognizing the uPAR84–95 sequence abolishes uPAR binding to FPR1 and prevents uPA-dependent cell adhesion and migration [92,187,188], the chemotaxis of melanoma cells and the invasion of matrices and endothelial monolayers [76].